Synlogic announces initiation of Synpheny-3 global, pivotal phase 3 study evaluating SYNB1934 for PKU

时间：2023-06-05

Jun 5, 2023 — Registrational study designed to support BLA submission of first-in-class biotherapeutic.

和度生物医药（上海）有限公司 沪ICP备2021004953号-1